Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine Augmented with Methylphenidate vs Placebo in ADHD Stimulant Non-Responders
NCT00485550Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atomoxetine, methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Started Jan 2004; status: completed.
02
Drugs
atomoxetinemethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00485550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00485550.